DUBLIN, Apr. 06, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the "Site-Specific Drug Delivery Market, By Application (Pulmonary, Ocular, Oncology, CNS, Cardiovascular) - World Forecasts to 2022" report to their offering.
It is anticipated that the global site specific drug delivery market will cross US$ 114 Billion by 2022. The growth of the market is likely to be driven by expanding drug discovery applications, rising chronic disease incidences, and increasing research related activities for exploring drug delivery therapeutic applications.
The advent of site specific/targeted drug delivery has revolutionized the drug delivery industry. This technique is allowing a previously unattainable level of drug delivery with greater efficiency to target organs and tissues. Due to this ability, the share of site specific drug delivery is incessantly increasing in the drug delivery industry.
The major application areas of targeted drug delivery pulmonary, ocular, oncology, and others including CNS, cardiovascular, etc. Oncology based application is the largest area of application of targeted drug delivery. This large share can be attributed to various research related activities conducted for developing targeted drug delivery approach for cancer.
Moreover, the report also contains the market share of major regions, including North America, Europe, and Asia Pacific. North America holds the largest market share, while Asia Pacific is expected to witness highest growth in the coming years, i.e. 2016-2022. The major reasons for the high growth are the ongoing researches in China and Australia, which is expanding therapeutic applications of site specific drug delivery to brain disorders. North America and Europe are expected to grow at a modest rate due to less stringent regulatory approval process and advancements in drug delivery technique.
The last segment of the report is entirely devoted to profiling leading companies of the targeted drug delivery industry, including some major players like Celgene Corporation, Arrowhead Pharma, Intezyne, Endocyte, BioDelivery Sciences International, PharmaIN, Mirus Bio, Savara, etc.
- Increasing Complexity of Drug Molecules
- Need for Improved Site-Specific Drug Delivery
- Advent of Nanotechnology in Site-Specific Drug Delivery
- Increasing Investments
- Complexity in Biopharma Supply Chain & Operations
- Issues in Quality Compliance & Regulatory Screening
- Increasing R&D Spending in Site-Specific Drug Delivery Technologies
- Surging Demand for In-Licensing Drug Delivery Products & Technologies
- Arrowhead Pharmaceuticals, Inc.
- BioDelivery Sciences International, Inc.
- Celgene Corporation
- Delpor, Inc.
- Endocyte, Inc.
- Intezyne, Inc.
- Kurve Technology, Inc.
- Mirus Bio LLC.
- Savara Inc.
For more information about this report visit http://www.researchandmarkets.com/research/fncr9l/sitespecific
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/world-114-billion-site-specific-drug-delivery-market-by-application-pulmonary-ocular-oncology-cns-cardiovascular---forecasts-to-2022---research-and-markets-300436058.html
SOURCE Research and Markets